Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Interest & Investment Income (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Interest & Investment Income data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 20.49% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $8.2 million, down 7.4%, while the annual FY2025 figure was $8.2 million, 7.4% down from the prior year.
  • Interest & Investment Income reached $2.0 million in Q4 2025 per CTNM's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.7 million in Q3 2024 and bottomed at $401000.0 in Q1 2023.
  • Average Interest & Investment Income over 3 years is $1.8 million, with a median of $2.0 million recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: surged 307.98% in 2024, then fell 28.58% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $1.8 million in 2023, then surged by 41.23% to $2.5 million in 2024, then fell by 20.49% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.